查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447720

HER2+ 胃癌市场评估：按治疗类型、阶段、最终用户和地区划分的机会和预测（2017-2031 年）

HER2+ Gastric Cancer Market Assessment, By Therapy Type, By Stage, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 232 Pages | 商品交期: 3-5个工作天内

价格

全球 HER2+ 胃癌市场规模将从 2023 年的 13.045 亿美元增长到 2031 年的 17.059 亿美元，在 2024 年至 2031 年的预测期内复合年增长率为 3.37%。

由于胃癌病例数增加，HER2+胃癌市场正在持续成长。 所有年龄层的病例都有所增加。 技术进步、研发投资增加以及政府措施也正在推动市场发展。 胃癌的盛行率在全球范围内迅速增加，几乎占不同类型癌症的 5%。 市场正在经历解决方案的技术进步，这些解决方案可以在更短的时间内以更高的准确性诊断癌症。 製药商正在开发更有效且与患者身体相容的药物。

胃癌盛行率不断上升

胃癌的盛行率正在迅速增加。 这种疾病盛行率上升的可能原因有很多，包括生活方式和饮食习惯的改变以及人口因素。 此类胃癌在分子层面上与其他类型不同，因此需要采用不同的标靶治疗方法。 随着胃癌在各年龄层尤其是老年人中的盛行率持续上升，对有效治疗和创新治疗方法的需求也在增加。 应对这项挑战需要透过开发先进的诊断方法来重点关注早期发现，提高人们对该疾病的认识以及定期健康检查的重要性。

技术进步

诊断技术的进步也对市场产生重大影响。 这些进展将彻底改变胃癌的识别、治疗和监测，最终有利于患者的预后。 现代诊断技术，例如具有高清影像的内视镜检查，可以准确地观察胃黏膜，从而可以在早期发现异常和病变。 透过先进的影像方式，如磁振造影 (MRI) 和正子断层扫描 (PET)，可以对疾病进展进行准确的分期和监测。 分子生物标记分析透过检测与胃癌相关的特定遗传和分子变化，正在彻底改变诊断领域。 此方法可用于风险评估、早期检测和治疗效果预测。

机器学习和人工智慧的整合也提高了诊断准确性。 可以使用人工智慧演算法分析大型资料集，以找到指向胃癌的小模式和特征。 这可以实现更快、更准确的诊断。 世界向远距医疗和数位医疗解决方案的转变使得获得专家建议、第二意见和远距咨询变得更加容易，特别是在卫生基础设施薄弱的地区。 这些进展将使胃癌的早期检测成为可能，为医生提供做出明智的治疗决策所需的信息，并支持制定量身定制的治疗方法。

本报告调查了全球 HER2+ 胃癌市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析。、监管框架、案例主要公司的研究、竞争格局和概况。

目录

第1章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第4章全球HER2+胃癌市场展望

  • 市场规模/预测
  • 依治疗类型
    • 化疗
    • 免疫治疗
    • 放射治疗
    • 标靶治疗
    • 其他
  • 依阶段
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段
  • 按最终用户
    • 医院
    • 专科诊所
    • 门诊手术中心
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第5章全球 HER2+ 胃癌市场展望：按地区

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 依治疗类型
  • 依阶段
  • 按最终用户
  • 按地区

第7章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑制生长的因素（问题/抑制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第10章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（主要公司）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析（%，2023 年）
  • 併购/合资企业（如果适用）
  • SWOT 分析（针对 5 位市场参与者）
  • 专利分析（如果适用）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
  • Hutchison Medipharma
  • LintonPharm Ltd
  • Shanghai Henlius Biotech Inc
  • Sanofi S A
  • Pfizer Inc.
  • Novartis AG
  • Abott Inc.

第 14 章策略建议

第15章关于我们公司/免责声明

Product Code: MX11127

Global HER2+ gastric cancer market is projected to witness a CAGR of 3.37% during the forecast period 2024-2031, growing from USD 1304.5 million in 2023 to USD 1700.59 million in 2031. Globally, gastric cancer ranks third in terms of cancer-related deaths and is the sixth most frequent type of cancer. Although there are no symptoms associated with early stomach cancer, some people receive confirmation about the cancer once they are diagnosed. A growth-promoting protein called HER2 is overexpressed on the surface of stomach cancer cells and treatment for these cancers often involves the use of drugs that specifically target the HER2 protein.

The HER2+ gastric cancer market is experiencing growth due to rising numbers of stomach cancer cases. The rise in these cases is seen across all the ages. Technological advancements, increasing investments in R&D, along with governments initiatives are also fueling the market. The prevalence of stomach cancer is increasing at a rapid rate globally, making it almost 5% of all different types of cancer. The market is experiencing technological advancements in terms of solutions that are capable of diagnosing cancer with less time and high accuracy. Pharmaceutical manufacturers are developing drugs that are more effective and compatible with patient's body.

In February 2022, Prime Research Institute and Ono Pharmaceuticals Co., along with Bristol-Myers Squibb, entered a contractual based collaboration to start a large scale, industry sponsored, clinical investigation involving patients with gastric cancer who were undergoing a treatment with Opdivo in combination with chemotherapy. "CyberOncology". It is a data input system developed by PRiMER-R that standardizes, organizes, manages, and integrates real-world data collected from routine cancer clinical practices.

Increasing Prevalence of Gastric Cancer

The prevalence of gastric cancer is rising at a rapid pace. There may be various reasons for the rising prevalence of this disease such as changing lifestyles, dietary habits, and population and demographics. However, what triggers it in the body may be over-expression or over-proliferation of HER2 protein that is present in the body. This form of gastric cancer is different from other types on a molecular level, due to which it is required to be treated differently through targeted therapies. As the prevalence of gastric cancer continues to rise in all age groups, especially the elderly, the demand for effective therapies and innovative treatment approaches also grows. This challenge needs to be addressed by emphasizing more on early detection by developing advanced diagnostic methods, spreading awareness to people about the disease, and communicating the importance of getting regular health checkups. According to a recent study published by ICMR, the number of Indians suffering from cancer is expected to grow to 29.8 million in the year 2025, from 26.7 million in 2021. Accordingly, talking about the burden of cancers in India, seven cancer types account for more than 40% of the total disease burden, whereas gastric cancer itself accounts for 5.2% alone.

Advancements in Technology

Technological advancements made for diagnosis have been playing a major role in influencing the global market for gastric cancer therapy. These developments are revolutionizing the identification, treatment, and monitoring of stomach cancer, which will ultimately benefit patients' prognosis. Modern diagnostic techniques, such as endoscopy with high-definition imaging, enable precise visualization of the stomach lining and detection of anomalies and lesions in their early stages. Accurate staging and disease progression monitoring are made possible by advanced imaging modalities like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Molecular biomarker analysis is transforming the field of diagnosis by detecting particular genetic and molecular changes linked to stomach cancer. This method helps with risk assessment, early detection, and treatment response prediction.

Integration of machine learning and artificial intelligence (AI) improves diagnostic precision. Large datasets may be analyzed by Al algorithms, which can then be used to find small patterns and traits that point to stomach cancer. This allows for earlier and more accurate diagnosis. Access to expert advice, second opinions, and remote consultations is becoming easier due to the global shift towards telemedicine and digital health solutions, especially in areas with weak healthcare infrastructure. These developments enable early detection of stomach cancer, provide doctors with the information they need to make well-informed treatment decisions and support the creation of tailored therapeutic methods.

In September 2022, Henlius' HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanized monoclonal antibody (mAb) injection, underwent a phase 1 clinical trial in patients with advanced solid tumors overexpressing HER2. The study's findings proved that HLX22 is safe and clinically effective.

Immunotherapies are Dominating the Market

Immunotherapy utilizes the body's immune system to recognize and eliminate cancer cells. Treatment options for gastric cancer are limited but immunotherapy has emerged as a clinically advanced alternative. Immune checkpoint inhibitors are a part of immunotherapies that have gained traction over the past few years. Checkpoint proteins like PD-1, PD-L1 and CTLA-4, which are exploited by the cancer cells to evade the immune response, are targeted by these drugs. The immune checkpoint inhibitors block these proteins and hence enable the immune system to build a strong attack against cancer. There have been times when patients who stopped responding to any other therapies have shown great results after going through immunotherapy. It also gives an experience of prolonged survival and a better quality of life. Combining immunotherapy with other therapies like targeted therapy and chemotherapy has proven to be of maximum effectiveness with the potential to stimulate long-lasting immune responses. The dominance of Immunotherapy flags a shift in this market, enabling rapid evolution of the market.

For instance, stage 1 of the worldwide phase III trial enrollment was completed in January 2022 by LintonPharm Co., Ltd., a biopharmaceutical firm based in China that specializes in the development of T cell-engaging bispecific antibodies for cancer immunotherapy. In this experiment, adult patients with advanced gastric cancer and peritonitis were assessed for safety and effectiveness with a bispecific monoclonal antibody called catumaxomab (GCPC).

North America to Dominate Gastric Cancer Market

Countries from North America, such as the United States, Canada, and Mexico, are contributing to market expansion due to the prevalence of gastric cancer, the availability of advanced healthcare infrastructure, the availability of healthcare professionals, and high healthcare expenditure. There is a significant burden of gastric cancer in North America, with millions of new cases being reported each year. The availability of advanced technologies, drugs, and diagnostics that give results faster and with more precision, modern infrastructure, vaccinations, and all the possible treatment options have created a very favorable environment for the development and expansion of this market in North America. Moreover, with the presence of many leading biopharmaceuticals in the region that have a strong and established pipeline of HER2+ gastric cancer treatments, the region is prone to market expansion with continued investment from the government and pharmaceutical companies.

According to statistics published in 2024 by the American Cancer Society for stomach cancer in the United States, there are about 26,890 new cases of gastric cancer, out of which 16,160 were recorded in men and 10,730 in women. There are about 10,880 deaths associated with this type of cancer. Out of which 6490 are men and 4390 are women. Stomach cancer accounts for about 1.5% of all new cancers diagnosed in the US, each year.

Future Market Scenario (2024 - 2031F)

The market for HER2+ gastric cancer is anticipated to further rise as people are becoming aware of the molecular subtypes of cancer. Future developments in this market are expected to be influenced by improvements in diagnostics and newly available treatment options, specifically combination therapy. Industry players must continue to collaborate and comply with changing regulatory standards to improve patient outcomes. Since this market has the potential to revolutionize the way illness is treated, if research and development efforts are sustainable, it can provide patients with a better quality of life. Partnerships and collaborations among pharmaceutical companies, healthcare providers, and patient advocacy groups are critical to meet the changing demands of patients with gastric cancer.

For example, in April 2022, BDR Pharmaceuticals introduced a drug called Furmecil, which is an oral generic medicine developed to treat patients with advanced gastric cancer. It is known to be the combination of three drugs - Tegafur, Gimeracil, and Oteracil. This combination has shown to be highly effective and safe as suggested by the BDR Pharmaceuticals itself.

Key Players Landscape and Outlook

There are several key players in the global HER2+ gastric cancer market. Currently, many competitors control most of the market. Among the businesses that are currently governing the market shares are AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm Ltd, Shanghai Henlius Biotech Inc, Sanofi S A, Pfizer Inc., Novartis AG, Abott Inc., etc. These companies are leading the market share due to their continuous efforts toward R&D, technological advancements, and drug development that is effective and reliable.

In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co. Ltd jointly stated that a breakthrough therapy designation was granted to a HER2 specific antibody (KN026) combined with chemotherapy for treating gastric cancer and gastroesophageal junction cancer.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global HER2+ Gastric Cancer Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Therapy Type
    • 4.2.1.Chemotherapy
    • 4.2.2.Immunotherapy
    • 4.2.3.Radiation Therapy
    • 4.2.4.Targeted Therapy
    • 4.2.5.Others
  • 4.3.By Stage
    • 4.3.1.Stage I
    • 4.3.2.Stage II
    • 4.3.3.Stage III
    • 4.3.4.Stage IV
  • 4.4.By End-user
    • 4.4.1.Hospitals
    • 4.4.2.Specialty Clinics
    • 4.4.3.Ambulatory Surgical Center
    • 4.4.4.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South End-user America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global HER2+ Gastric Cancer Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Therapy Type
      • 5.1.2.1.Chemotherapy
      • 5.1.2.2.Immunotherapy
      • 5.1.2.3.Radiation Therapy
      • 5.1.2.4.Targeted Therapy
      • 5.1.2.5.Others
    • 5.1.3.By Stage
      • 5.1.3.1.Stage I
      • 5.1.3.2.Stage II
      • 5.1.3.3.Stage III
      • 5.1.3.4.Stage IV
    • 5.1.4.By End-user
      • 5.1.4.1.Hospitals
      • 5.1.4.2.Specialty Clinics
      • 5.1.4.3.Ambulatory Surgical Center
      • 5.1.4.4.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Therapy Type
      • 5.1.5.2.1.Chemotherapy
      • 5.1.5.2.2.Immunotherapy
      • 5.1.5.2.3.Radiation Therapy
      • 5.1.5.2.4.Targeted Therapy
      • 5.1.5.2.5.Others
      • 5.1.5.3.By Stage
      • 5.1.5.3.1.Stage I
      • 5.1.5.3.2.Stage II
      • 5.1.5.3.3.Stage III
      • 5.1.5.3.4.Stage IV
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospitals
      • 5.1.5.4.2.Specialty Clinics
      • 5.1.5.4.3.Ambulatory Surgical Center
      • 5.1.5.4.4.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Therapy Type
  • 6.2.By Stage
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.AstraZeneca PLC
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Bayer AG
  • 13.3.Bristol-Myers Squibb
  • 13.4.Ono Pharmaceutical Co. Ltd
  • 13.5.Hutchison Medipharma
  • 13.6.LintonPharm Ltd
  • 13.7.Shanghai Henlius Biotech Inc
  • 13.8.Sanofi S A
  • 13.9.Pfizer Inc.
  • 13.10.Novartis AG
  • 13.11.Abott Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 2.Global HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 4.Global HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 5.Global HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global HER2+ Gastric Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7.North America HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 8.North America HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 10.North America HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 11.North America HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13.United States HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 14.United States HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 16.United States HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 17.United States HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 19.Canada HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 21.Canada HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 22.Canada HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 24.Mexico HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 26.Mexico HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 27.Mexico HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 29.Europe HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 31.Europe HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 32.Europe HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 35.Germany HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 37.Germany HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 38.Germany HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39.France HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 40.France HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 42.France HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 43.France HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 45.Italy HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 47.Italy HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 48.Italy HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 50.United Kingdom HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 52.United Kingdom HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 53.United Kingdom HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 55.Russia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 57.Russia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 58.Russia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 60.Netherlands HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 62.Netherlands HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 63.Netherlands HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 65.Spain HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 67.Spain HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 68.Spain HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 70.Turkey HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 72.Turkey HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 73.Turkey HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 75.Poland HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 77.Poland HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 78.Poland HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 80.South America HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 82.South America HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 83.South America HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 86.Brazil HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 88.Brazil HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 89.Brazil HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 91.Argentina HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 93.Argentina HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 94.Argentina HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 96.Asia-Pacific HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 98.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 99.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101.India HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 102.India HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 104.India HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 105.India HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106.China HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 107.China HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 109.China HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 110.China HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 112.Japan HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 114.Japan HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 115.Japan HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 117.Australia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 119.Australia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 120.Australia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 122.Vietnam HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 124.Vietnam HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 125.Vietnam HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 127.South Korea HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 129.South Korea HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 130.South Korea HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 132.Indonesia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 134.Indonesia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 135.Indonesia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 137.Philippines HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 139.Philippines HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 140.Philippines HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 142.Middle East & Africa HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 144.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 145.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 148.Saudi Arabia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 150.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 151.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 153.UAE HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 155.UAE HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 156.UAE HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 158.South Africa HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 160.South Africa HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 161.South Africa HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Therapy Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 163.By Stage Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Million) & Growth Rate (%), 2023